382 results match your criteria Dementia: Overview of Pharmacotherapy


WINDOW consortium: A path towards increased therapy efficacy against glioblastoma.

Drug Resist Updat 2018 Sep 30;40:17-24. Epub 2018 Oct 30.

Department of Neurosurgery, Brain Tumor Center Amsterdam, Amsterdam University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HZ, Amsterdam, Netherlands. Electronic address:

Glioblastoma is the most common and malignant form of brain cancer, for which the standard treatment is maximal surgical resection, radiotherapy and chemotherapy. Despite these interventions, mean overall survival remains less than 15 months, during which extensive tumor infiltration throughout the brain occurs. The resulting metastasized cells in the brain are characterized by chemotherapy resistance and extensive intratumoral heterogeneity. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13687646183004
Publisher Site
http://dx.doi.org/10.1016/j.drup.2018.10.001DOI Listing
September 2018
7 Reads

Advances in the pharmacotherapeutic management of dementia with Lewy bodies.

Expert Opin Pharmacother 2018 Oct 13;19(15):1643-1653. Epub 2018 Sep 13.

a Department of Clinical and Experimental Medicine , Unit of Neurology, University of Pisa , Pisa , Italy.

Introduction: Dementia with Lewy bodies (DLB) is the second most common type of dementia in people over 65 years of age. Given the complex clinical phenotype, the management of DLB may be challenging, especially considering that there is limited evidence about specific interventions, and there are currently no Food and Drug Administration (FDA)/European Medicines Agency (EMA)-approved medications. Areas covered: This article provides an overview of the current pharmacotherapy in DLB and gives review to the most recent drug candidates in clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1519548DOI Listing
October 2018
2 Reads

Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer's disease.

Authors:
Benjamin Cretin

Expert Opin Pharmacother 2018 Aug 14;19(11):1201-1209. Epub 2018 Jul 14.

a Unité de Neuropsychologie , Service de Neurologie des Hôpitaux Universitaires de Strasbourg , Strasbourg , France.

Introduction: Alzheimer's disease (AD)-related epileptic comorbidity is now well documented and appears to have been previously underestimated. Prescribing antiepileptic drugs (AEDs) in AD patients aims at preventing seizure-related morbi-mortality and the occurrence of deleterious status epilepticus. At the earlier stages of the disease, some clinicians even expect a disease-modifying effect. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1496237DOI Listing
August 2018
25 Reads

Iron and Alzheimer's Disease: An Update on Emerging Mechanisms.

J Alzheimers Dis 2018 ;64(s1):S379-S395

Melbourne Dementia Research Centre, The Florey Institute of Neuroscience & Mental Health, The University of Melbourne, Parkville, VIC, Australia.

Iron is a crucial transition metal for life and is the most abundant transition metal in the brain. However, iron's biological utility as an effective redox cycling metal also endows it with the potential to catalyze production of noxious free radicals. This "Janus-faced" nature of iron demands a tight regulation of cellular its metabolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-179944DOI Listing
January 2018
1 Read

Apelin, a promising target for Alzheimer disease prevention and treatment.

Neuropeptides 2018 Aug 23;70:76-86. Epub 2018 May 23.

Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Paramedical Faculty, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address:

Alzheimer's disease (AD) is a progressive neurodegenerative disease with high outbreak rates. It is estimated that about 35 million individuals around the world suffered from dementia in 2010. AD is expected to increase twofold every 20 years and, by 2030, approximately 65 million people could suffer from this illness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.npep.2018.05.008DOI Listing
August 2018
2 Reads

Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy.

J Pharm Pharmacol 2018 Aug 16;70(8):985-993. Epub 2018 Apr 16.

Department of Biotechnology, National Institute of Technology Raipur, Raipur, India.

Objectives: Alzheimer's disease (AD) has become the primary cause of dementia. It shows a progressive cognitive dysfunction with degenerating neurons. Acetylcholine receptors (AChRs) propagate the cognitive ability and it consists of two primary members namely muscarinic (mAChRs) and nicotinic receptors (nAChRs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jphp.12919DOI Listing
August 2018
1 Read
2.161 Impact Factor

An Overview on the Clinical Development of Tau-Based Therapeutics.

Authors:
Miguel Medina

Int J Mol Sci 2018 Apr 11;19(4). Epub 2018 Apr 11.

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Queen Sofia Foundation Alzheimer Center, CIEN Foundation, Carlos III Institute of Health, 28031 Madrid, Spain.

Tauopathies such as Alzheimer's disease (AD), frontotemporal lobar degeneration, or progressive supranuclear palsy constitute a group of brain disorders defined by neurodegeneration and the presence of tau aggregates in the affected brains regions. Tau is a microtubule-associated protein that accumulates in the cytosol under pathological conditions, steering the formation of aggregates or inclusions thought to be involved in the degeneration and neuronal death associated with these diseases. Despite a substantial and unmet medical need for novel, more effective disease-modifying therapies for the treatment of AD and tauopathies, the last couple of decades have seen numerous drug development undertakings primarily focused on β-amyloid, with disappointing results to date. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms19041160DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979300PMC

[Pharmacologic Therapies for Different Types of Dementia].

Brain Nerve 2018 Mar;70(3):211-220

Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University.

We provide a general overview of pharmacologic treatments for different types of dementia in light of the Guidelines on the Clinical Management of Dementia in Japan 2017, clinical data not addressed in those guidelines, and the results of observational studies, focusing mainly on the treatment of Alzheimer-type dementia. In everyday clinical practice, patients must be provided with personalized treatment that strikes a balance between evidence-based treatment, as described in the guidelines and actual clinical circumstances. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11477/mf.1416200983DOI Listing
March 2018
1 Read

Topical Discoveries on Multi-Target Approach to Manage Alzheimer's Disease.

Curr Drug Metab 2018 ;19(8):704-713

Quaid-e-Azam University, Islamabad, Pakistan.

Background: Alzheimer's disease (AD) is recognized as progressive multifaceted and multi-factorial neurodegenerative disorder which causes dementia among elderly people. Although, researchers in this field have put considerable efforts for the investigation of novel and appropriate therapeutic measures towards the cure of AD, unfortunately, no effective prevention therapy for this disease is available till date. In fact, various aspects involved in the onset and progression of AD are still disputed or uncovered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389200219666180305152553DOI Listing
November 2018
1 Read

Flavonoids in the Treatment of Alzheimer's and Other Neurodegenerative Diseases.

Curr Med Chem 2018 ;25(27):3228-3246

Department of Biotechnology and Bioscience, University of Milano-Bicocca, Milan, Italy.

Flavonoids are phytochemicals present in almost all terrestrial plants and, as a consequence, in plant-based foods, and thus consumed by humans through diet. Recent evidences suggest that several flavonoids have positive effects against dementia and Alzheimer's disease, reversing age-related declines in neurocognitive performances. In this review, we provide a general classification of natural and synthetic flavonoids, a description of their physico-chemical properties, in particular their redox properties and stability, and an extensive overview about their biological activities and structure-activity relationship in the field of neurodegenerative diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/0929867325666180209132125DOI Listing
September 2018
3 Reads

Research and development of anti-Alzheimer's disease drugs: an update from the perspective of technology flows.

Expert Opin Ther Pat 2018 Apr 13;28(4):341-350. Epub 2018 Feb 13.

a State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences , University of Macau , Taipa , China.

Introduction: Today, over 20 million people suffer from Alzheimer's disease (AD) worldwide. AD has become a critical issue to human health, especially in aging societies, and therefore it is a research hotspot in the global scientific community. The technology flow method differs from traditional reviews generating an informative overview of the research and development (R&D) landscape in a specific technological area. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543776.2018.1439475DOI Listing
April 2018
3 Reads

Studies on the interaction of NMDA receptor antagonist memantine with cell membranes: A mini-review.

Chem Biol Interact 2018 Mar 31;283:47-50. Epub 2018 Jan 31.

Malopolska Centre of Biotechnology, Jagiellonian University, Kraków, Poland; Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland.

Memantine is an NMDA receptor antagonist clinically used for the treatment of moderate to severe Alzheimer's disease. Currently, it is the only NMDA receptor antagonist drug marketed against this disease. Despite the large number of publications regarding its clinical and therapeutic use, studies related to its mechanism of action are still inconclusive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cbi.2018.01.022DOI Listing
March 2018
4 Reads

Coumarin: A Natural, Privileged and Versatile Scaffold for Bioactive Compounds.

Molecules 2018 Jan 27;23(2). Epub 2018 Jan 27.

Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "Aldo Moro", via E. Orabona 4, I-70125 Bari, Italy.

Many naturally occurring substances, traditionally used in popular medicines around the world, contain the coumarin moiety. Coumarin represents a privileged scaffold for medicinal chemists, because of its peculiar physicochemical features, and the versatile and easy synthetic transformation into a large variety of functionalized coumarins. As a consequence, a huge number of coumarin derivatives have been designed, synthesized, and tested to address many pharmacological targets in a selective way, e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules23020250DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017103PMC
January 2018
1 Read

Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?

eNeurologicalSci 2017 Sep 2;8:44-53. Epub 2017 Jul 2.

Hospital Santa Creu i Sant Pau, Ciberned, Universitat Autònoma de Barcelona, Universitat Oberta de Catalunya, Barcelona, Spain.

Advanced Parkinson's disease (APD) is characterized by increased functional disability, caused by motor complications, the presence of axial symptoms, and emergent disease- and drug-related non-motor symptoms. One of the advanced therapies available is intrajejunal infusion of levodopa/carbidopa intestinal gel (LCIG); however, patient selection for this treatment is sometimes difficult, particularly because of overlapping indications with other alternatives. In recent years, strong evidence has supported the use of LCIG in treating motor fluctuations associated with APD, and several clinical studies provide emerging evidence for additional benefits of LCIG treatment in certain patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ensci.2017.06.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730910PMC
September 2017
32 Reads

RD Lawrence Lecture 2017 Incretins: the intelligent hormones in diabetes.

Authors:
V A Gault

Diabet Med 2018 01 1;35(1):33-40. Epub 2017 Nov 1.

School of Biomedical Sciences, University of Ulster, Coleraine, UK.

The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have attracted considerable scientific and clinical interest due largely to their insulin-releasing and glucose-lowering properties. Indeed, GLP-1-based therapies are now key treatment options for many people with diabetes worldwide. In contrast, GIP-based agents have yet to reach the clinic based primarily on the impaired insulinotropic action of GIP observed in people with diabetes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dme.13522DOI Listing
January 2018

Very Late-Onset Schizophrenia-Like Psychosis: A Clinical Update.

J Psychosoc Nurs Ment Health Serv 2018 Jan 9;56(1):37-47. Epub 2017 Oct 9.

Psychosis symptoms (delusions and hallucinations) are multifactorial in origin and, in later life, occur in the context of schizophrenia, delirium, dementia, delusional and schizophrenia-like disorders, mood disorders, and alcohol or substance abuse. The current article provides a clinical overview of very late-onset (after age 60) schizophrenia-like psychosis (VLOSLP), summarizing the literature on treatment options and reflecting on the role of psychiatric-mental health nurses (PMHNs). Increased awareness of the clinical presentation, key features, and evidence-based treatment options will assist PMHNs to confidently recognize this often under-diagnosed disorder and adopt a more assertive role in terms of engagement and follow up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3928/02793695-20170929-02DOI Listing
January 2018
15 Reads

The present and future of pharmacotherapy of Alzheimer's disease: A comprehensive review.

Eur J Pharmacol 2017 Nov 1;815:364-375. Epub 2017 Oct 1.

Department of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India. Electronic address:

Alzheimer's disease (AD) is a generalized term used for the loss in memory and other intellectual abilities on levels serious enough to interfere with daily life. It accounts for 60-80% of dementia cases. The characteristic features include aggregation of Amyloid-Beta (Aβ) plaques and Tau Protein Tangles in the nervous tissue of brain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2017.09.043DOI Listing
November 2017
16 Reads

Phosphodiesterase-4B as a Therapeutic Target for Cognitive Impairment and Obesity-Related Metabolic Diseases.

Adv Neurobiol 2017 ;17:103-131

School of Biomedical Sciences, University of Leeds, Leeds, LS2 9JT, UK.

People in modern, affluent societies are living longer but also becoming increasingly overweight. With increased life expectancy comes increased risk of developing age-related cognitive decline and neurodegenerative diseases, such that an increasing proportion of life may be lived with cognitive impairment as age increases. Obesity is associated with poorer cognitive function in elderly subjects, and often leads to ill-health arising from various complications such as metabolic syndrome and type-2 diabetes mellitus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-58811-7_5DOI Listing
January 2018
14 Reads

[Treatment of dementia].

Ned Tijdschr Geneeskd 2017 ;161:D1851

UMC Utrecht, Utrecht.

- Treatment options for patients with dementia are limited. This article provides an overview of possible interventions, both pharmaceutical and non-pharmaceutical, for Alzheimer's disease, vascular dementia and mixed dementia.- Pharmaceutical treatment options include cholinesterase inhibitors, memantine and experimental medication. Read More

View Article

Download full-text PDF

Source
June 2018
6 Reads

The Medicinal Chemistry of Natural and Semisynthetic Compounds against Parkinson's and Huntington's Diseases.

ACS Chem Neurosci 2017 11 15;8(11):2356-2368. Epub 2017 Sep 15.

Department of Pharmaceutical and Pharmacological Sciences, University of Padova , Padova 35131, Italy.

Among the diseases affecting the central nervous system (CNS), neurodegenerations attract the interest of both the clinician and the medicinal chemist. The increasing average age of population, the growing number of patients, and the lack of long-term effective remedies push ahead the quest for novel tools against this class of pathologies. We present a review on the state of the art of the molecules (or combination of molecules) of natural origin that are currently under study against two well-defined pathologies: Parkinson's disease (PD) and Huntington's disease (HD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acschemneuro.7b00283DOI Listing
November 2017

Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents.

Eur J Med Chem 2017 Oct 29;139:153-167. Epub 2017 Jul 29.

Université Caen Normandie, France; UNICAEN, CERMN - EA 4258, FR CNRS 3038 INC3M, SF 4206 ICORE, bd Becquerel, F-14032 Caen, France. Electronic address:

Alzheimer's Disease (AD) is a neurodegenerative brain disorder in which many biological dysfunctions are involved. Among them, two main types of lesions were discovered and widely studied: the amyloid plaques and the neurofibrillary tangles (NFTs). These two lesions are caused by the dysfunction and the accumulation of two proteins which are, respectively, the beta-amyloid peptide and the tau protein. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2017.07.070DOI Listing
October 2017
13 Reads

Reasons for (not) discontinuing antipsychotics in dementia.

Psychogeriatrics 2018 Jan 26;18(1):13-20. Epub 2017 Jul 26.

Department Health Technology and Services Research, University of Twente, Enschede, The Netherlands.

Background: The gap between high antipsychotic prescription rates for patients with dementia and the guidelines' advice to prescribe cautiously indicates that barriers to discontinuation exist. This exploratory study used the theory of planned behaviour to give a first overview of the factors that influence physicians to discontinue antipsychotics in nursing home patients with dementia.

Methods: Forty-one physicians in the Netherlands completed an online survey based on the theory of planned behaviour. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/psyg.12280DOI Listing
January 2018
18 Reads

Classics in Chemical Neuroscience: Memantine.

ACS Chem Neurosci 2017 09 9;8(9):1823-1829. Epub 2017 Aug 9.

Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine , Nashville, Tennessee 37232, United States.

Memantine was the first breakthrough medication for the treatment of moderate to severe Alzheimer's disease (AD) patients and represents a fundamentally new mechanism of action (moderate-affinity, uncompetitive, voltage-dependent, N-methyl-d-aspartate (NMDA) receptor antagonist that exhibits fast on/off kinetics) to modulate glutamatergic dysfunction. Since its approval by the FDA in 2003, memantine, alone and in combination with donepezil, has improved patient outcomes in terms of cognition, behavioral disturbances, daily functioning, and delaying time to institutionalization. In this review, we will highlight the historical significance of memantine to AD (and other neuropsychiatric disorders) as well as provide an overview of the synthesis, pharmacology, and drug metabolism of this unique NMDA uncompetitive antagonist that clearly secures its place among the Classics in Chemical Neuroscience. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acschemneuro.7b00270DOI Listing
September 2017
7 Reads

Alzheimer's Disease: Dawn of a New Era?

J Pharm Pharm Sci 2017 ;20(0):184-225

School of Pharmacy, Chapman University, Irvine, CA, USA.

Alzheimer's disease (AD) is an irreversible neurodegenerative disease characterized by a progressive decline in cognition and memory, leading to significant impairment in daily activities and ultimately death. It is the most common cause of dementia, the prevalence of which increases with age; however, age is not the only predisposing factor. The pathology of this cognitive impairing disease is still not completely understood, which has limited the development of valid therapeutic options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18433/J3VS8PDOI Listing
December 2017
4 Reads

An Overview of New Possible Treatments of Alzheimer's Disease, Based on Natural Products and Semi-Synthetic Compounds.

Curr Med Chem 2017 Nov;24(34):3749-3773

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.

Background: Dementias and all related neurodegenerative diseases of the Central Nervous System (CNS) are a current issue arousing a great deal of interest in the international scientific community. This is due to the increasing number of patients suffering from these diseases. These pathologies represent a serious problem, not only concerning the quality of life of the patient, but in addition, the enormous economic efforts that society has to do for their treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/0929867324666170712161829DOI Listing
November 2017
3 Reads

Multi-targeting Strategies for Alzheimer's Disease Therapeutics: Pros and Cons.

Curr Top Med Chem 2017 ;17(27):3017-3061

Department of Microbiology, University of Calcutta, 35 Ballygunge Circular Road, Kolkata - 700 019. India.

Alzheimer's Disease (AD) is a single major cause of dementia in middle to old age individuals involving several different etiopathological mechanisms that are yet to be properly characterized. Major invariant and characteristic features consist of the progressive cerebral deposition of the Amyloid β-protein (Aβ) and the neurofibrillary degeneration through Neurofibrillary Tangles (NFT) formed by hyperphosphorylation of the tau proteins in the regions of the brain that deal with memory and cognition. There are at least five subgroups of AD that can be identified by determining Cerebrospinal Fluid (CSF) levels of Aβ1-42, tau and ubiquitin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568026617666170707130652DOI Listing
November 2017
4 Reads

Interplay between Autophagy, Exosomes and HIV-1 Associated Neurological Disorders: New Insights for Diagnosis and Therapeutic Applications.

Viruses 2017 07 6;9(7). Epub 2017 Jul 6.

Department of Immunology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.

The autophagy-lysosomal pathway mediates a degradative process critical in the maintenance of cellular homeostasis as well as the preservation of proper organelle function by selective removal of damaged proteins and organelles. In some situations, cells remove unwanted or damaged proteins and RNAs through the release to the extracellular environment of exosomes. Since exosomes can be transferred from one cell to another, secretion of unwanted material to the extracellular environment in exosomes may have an impact, which can be beneficial or detrimental, in neighboring cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/v9070176DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537668PMC
July 2017
35 Reads

The Complexity of Clinical Huntington's Disease: Developments in Molecular Genetics, Neuropathology and Neuroimaging Biomarkers.

Adv Neurobiol 2017 ;15:129-161

Centre for Brain Research, The University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder characterised by extensive neuronal loss in the striatum and cerebral cortex, and a triad of clinical symptoms affecting motor, cognitive/behavioural and mood functioning. The mutation causing HD is an expansion of a CAG tract in exon 1 of the HTT gene. This chapter provides a multifaceted overview of the clinical complexity of HD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-57193-5_5DOI Listing
November 2018
2 Reads

The Blood Brain Barrier and its Role in Alzheimer's Therapy: An Overview.

Curr Drug Targets 2018 ;19(2):155-169

RVS Technology Ammal College of Pharmacy, Coimbatore, Tamil Nadu - 643001. India.

Background: Alzheimer's disease (AD) is the most frequent age related neurodegenerative disorder. It represents 70% of all dementia. Millions of people have been affected by AD worldwide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389450118666170612100750DOI Listing
January 2018
11 Reads

Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.

Curr Drug Metab 2017 ;18(9):842-852

Department of Pharmacology and Toxicology, University of Hail, Hail. Saudi Arabia.

Background: Drug repurposing is an innovative approach as it provides new indications for already approved and established drugs. Due to high failure rates and cost involved in traditional drug development procedures, many pharmaceutical companies are primarily focusing on drug repurposing strategy. In Alzheimer disease (AD), existing therapeutic agents only provide symptomatic benefits and does not play a role in disease modification, therefore, an alternative strategy of repurposing can be used to inhibit neurodegeneracy process and other pathological complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389200218666170607101622DOI Listing
September 2018
8 Reads

Part 3: Impact of systemic conditions and medications on oral health.

Authors:
Diana Critchlow

Br J Community Nurs 2017 Apr;22(4):181-190

Senior Dental Officer, Northeast London NHS Foundation Trust, Dental Department, Grays Health Centre.

The people who are treated in the community setting will often have multiple comorbidities. Systemic medical conditions can have a negative impact on oral health. In addition, the medications used to treat systemic conditions may also themselves cause oral symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12968/bjcn.2017.22.4.181DOI Listing

WITHDRAWN: Interventions for fatigue and weight loss in adults with advanced progressive illness.

Cochrane Database Syst Rev 2017 04 7;4:CD008427. Epub 2017 Apr 7.

Faculty of Life and Health Sciences, University of Ulster, Shore Road, Newtownabbey, Co. Antrim Northern Ireland, UK, BT37 0QB.

Background: Fatigue and unintentional weight loss are two of the commonest symptoms experienced by people with advanced progressive illness. Appropriate interventions may bring considerable improvements in function and quality of life to seriously ill people and their families, reducing physical, psychological and spiritual distress.

Objectives: To conduct an overview of the evidence available on the efficacy of interventions used in the management of fatigue and/or unintentional weight loss in adults with advanced progressive illness by reviewing the evidence contained within Cochrane reviews. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD008427.pub3DOI Listing
April 2017
8 Reads

Pharmacological Management of Psychiatric Symptoms in Frontotemporal Dementia: A Systematic Review.

J Geriatr Psychiatry Neurol 2017 May 28;30(3):162-169. Epub 2017 Mar 28.

1 Department of Psychiatry, University of Milan, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy.

Psychiatric symptoms in patients with frontotemporal dementia (FTD) are highly prevalent and may complicate clinical management of these patients. Purpose of the present article is to present and discuss available data about the pharmacological treatment of psychiatric symptoms in patients with FTD. A research in the main database sources has been conducted to obtain an overview of the pharmacological management of psychiatric symptoms in patients with FTD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0891988717700506DOI Listing
May 2017
7 Reads

Defining the Relationship Between Hypertension, Cognitive Decline, and Dementia: a Review.

Curr Hypertens Rep 2017 Mar;19(3):24

Department of Neurology, Johns Hopkins University School of Medicine, Phipps 446D 600 North Wolfe St., Baltimore, MD, 21287, USA.

Hypertension is a highly prevalent condition which has been established as a risk factor for cardiovascular and cerebrovascular disease. Although the understanding of the relationship between cardiocirculatory dysfunction and brain health has improved significantly over the last several decades, it is still unclear whether hypertension constitutes a potentially treatable risk factor for cognitive decline and dementia. While it is clear that hypertension can affect brain structure and function, recent findings suggest that the associations between blood pressure and brain health are complex and, in many cases, dependent on factors such as age, hypertension chronicity, and antihypertensive medication use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11906-017-0724-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164165PMC
March 2017
7 Reads

Mitochondria in Alzheimer's Disease and Diabetes-Associated Neurodegeneration: License to Heal!

Handb Exp Pharmacol 2017 ;240:281-308

CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, 3004-517, Portugal.

Alzheimer's disease (AD) is a difficult puzzle to solve, in part because the etiology of this devastating neurodegenerative disorder remains murky. However, diabetes has been pinpointed as a major risk factor for the sporadic forms of AD. Several overlapping neurodegenerative mechanisms have been identified between AD and diabetes, including mitochondrial malfunction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/164_2017_3DOI Listing
December 2017
1 Read
2 Citations

Therapeutic potentials of herbal drugs for Alzheimer’s disease—An overview.

Indian J Exp Biol 2017 Feb;55(2):63-73

Alzheimer’s disease (AD) is a well known progressive neurodegenerative disorder having complex pathophysiology. Currently, drugs that are used symptomatically in the treatment of AD include acetylcholinesterase inhibitors (AChEIs) (rivastigmine, galantamine, donepezil) and N-methyl D-aspartate (NMDA) receptor antagonist (memantine). Limited bioavailability of these drugs stresses continuity of search for novel therapeutics for this slow growing but complex disease. Read More

View Article

Download full-text PDF

Source
February 2017

Research Advances and Detection Methodologies for Microbe-Derived Acetylcholinesterase Inhibitors: A Systemic Review.

Molecules 2017 Jan 23;22(1). Epub 2017 Jan 23.

Fujian Key Laboratory of Innate Immune Biology, Fujian Normal University, Fuzhou 350117, China.

Acetylcholinesterase inhibitors (AChEIs) are an attractive research subject owing to their potential applications in the treatment of neurodegenerative diseases. Fungi and bacteria are major producers of AChEIs. Their active ingredients of fermentation products include alkaloids, terpenoids, phenylpropanoids, and steroids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules22010176DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155930PMC
January 2017
5 Reads
1 Citation
2.420 Impact Factor

Management of Depression in Patients with Dementia: Is Pharmacological Treatment Justified?

Drugs Aging 2017 02;34(2):89-95

School of Psychiatry and Clinical Neurosciences (M573), Western Australian Centre for Health and Ageing (M573), Harry Perkins Institute of Medical Research, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009, Australia.

Depression in the context of dementia is common and contributes to poorer outcomes in individuals and those who care for them. Non-pharmacological treatments are the preferred initial approach to managing these symptoms but data in support of these are scarce. There are a number of pharmacological treatment options available to clinicians but efficacy is uncertain and concern about potential side effects in an aging and vulnerable population needs to be taken into consideration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40266-016-0434-6DOI Listing
February 2017

Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.

Authors:
Katarzyna Rygiel

Indian J Pharmacol 2016 Nov-Dec;48(6):629-636

Department of Family Practice, Medical University of Silesia, Katowice Zabrze, Poland.

Alzheimer's disease (AD) is a multifactorial, progressive neurodegenerative disorder with a poor prognosis, and thus, novel therapies for AD are certainly needed in a growing population of elderly patients or asymptomatic individuals, who are at risk for AD, worldwide. It has been established that some AD biomarkers such as amyloid-beta load in the brain, precede the onset of the disease, by approximately 20 years. Therefore, the therapy to prevent or effectively treat AD has to be initiated before the emergence of symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/0253-7613.194867DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155461PMC
June 2017
31 Reads

Effects of Ginkgo biloba on dementia: An overview of systematic reviews.

J Ethnopharmacol 2017 Jan 7;195:1-9. Epub 2016 Dec 7.

School of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. Electronic address:

Objective: To assess the cumulative evidence on the efficacy and effectiveness of Ginkgo biloba extract (GbE) in the treatment of dementia.

Design: Overview of systematic reviews.

Methods: PubMed/MEDLINE, EMBASE, Cochrane, and Google Scholar were searched in June 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jep.2016.12.005DOI Listing
January 2017
9 Reads

AVP-786 for the treatment of agitation in dementia of the Alzheimer's type.

Expert Opin Investig Drugs 2017 Jan 11;26(1):121-132. Epub 2016 Dec 11.

b Department of Psychiatry and Behavioural Neuroscience , St Louis University School of Medicine , St Louis , MO , USA.

Introduction: Agitation is common and distressing in patients with Alzheimer-type dementia, but safe, effective treatments remain elusive. Psychological treatments are first-line options, but they have limited efficacy. Off-label psychotropic medications are frequently used, but they also have limited effectiveness, and their use may have harmful side effects, including death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2017.1267726DOI Listing
January 2017
3 Reads

A Current Perspective on the Inhibition of Cholinesterase by Natural and Synthetic Inhibitors.

Curr Drug Metab 2017 ;18(2):96-111

King Fahd Medical Research Center, King Abdulaziz University, P.O. box 80216, Jeddah 21589. Saudi Arabia.

Majority of the observed cognitive and behavioral changes in Alzheimer's disease are postulated to be due to the deficiencies in cholinergic pathways of the brain. Enhancement of cholinergic transmission may thus stimulate the cholinergic receptors or prolong the availability of acetylcholine in synaptic cleft and hence improve the Alzheimer's disease associated symptoms. Of these two, the inhibition of cholinesterases (Acetylcholinesterase and Butyrylcholinesterase) by cholinesterase inhibitors is suggested to be a promising strategy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389200218666161123122734DOI Listing
September 2018
7 Reads
2.980 Impact Factor

Pioglitazone for the treatment of Alzheimer's disease.

Expert Opin Investig Drugs 2017 Jan 4;26(1):97-101. Epub 2016 Dec 4.

a Neurology Unit, Department of Pathophysiology and Transplantation , University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico , Milan , Italy.

Introduction: Alzheimer's disease (AD) is the most common cause of dementia in the elderly. Pharmacological treatment of AD includes Anticholinesterase Inhibitors (AChEIs) for mild-moderate AD, and memantine for severe AD. These drugs provide mainly symptomatic short-term benefits without clearly influencing the progression of the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2017.1265504DOI Listing
January 2017
6 Reads

Determinants of the nurses' and nursing assistants' request for antipsychotics for people with dementia.

Int Psychogeriatr 2017 03 21;29(3):475-484. Epub 2016 Nov 21.

Department of General Practice,University of Groningen,University Medical Center Groningen,Groningen,the Netherlands.

Background: Although physicians are responsible for writing the antipsychotic prescriptions for patients with dementia, the initiative is often taken by nurses or nursing assistants. To reduce antipsychotics uses, one needs to understand the reasons for nurses and nursing assistants to request them. This study gives an overview of the influencing factors for this request based on the Theory of Planned Behavior in which attitude, beliefs, and behavioral control is thought to influence the intention to request, which in turn affects the behavior to request for a prescription. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1041610216001897DOI Listing
March 2017
11 Reads

Capgras syndrome in Parkinson's disease: two new cases and literature review.

Neurol Sci 2017 Feb 15;38(2):225-231. Epub 2016 Nov 15.

Department of Neurology, Movement Disorders Center, Policlinico Universitario Monserrato, University of Cagliari, SS 554 Bivio per Sestu, Monserrato, 09042, Cagliari, Italy.

The Capgras syndrome (CS) is a rare psychiatric disorder. CS is classified as a delusional misidentification syndrome. Initially, CS was described in paranoid schizophrenia and schizoaffective disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10072-016-2765-9DOI Listing
February 2017
11 Reads

[Memantine as add-on medication to acetylcholinesterase inhibitor therapy for Alzheimer dementia].

Authors:
R Haussmann M Donix

Nervenarzt 2017 Jan;88(1):40-45

Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland.

Currently available data indicate superior therapeutic effects of combination treatment for Alzheimer dementia with memantine and acetylcholine esterase inhibitors in certain clinical contexts. Out of five randomized, placebo-controlled, double-blind trials two showed superior therapeutic effects in comparison to monotherapy with acetylcholinesterase inhibitors regarding various domains. Recently published meta-analyses and cost-benefit analyses also showed positive results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00115-016-0237-3DOI Listing
January 2017

Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases.

Drug Dev Res 2016 12 4;77(8):458-468. Epub 2016 Nov 4.

Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, Idaho State University, Pocatello, Idaho, 83209.

Preclinical Research Neuropsychiatric symptoms are currently recognized as a common burden in patients suffering from Alzheimer's disease (AD), Parkinson's disease (PD), and many other neurodegenerative disorders. Earlier theories positing that these symptoms emerge predominantly in patients with late-stage disease have been largely dismissed. It is now generally accepted that many neuropsychiatric symptoms commonly manifest very early in neurodegenerative disease stages, and in many cases are even considered prodromal indicators. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ddr.21368DOI Listing
December 2016
1 Read

Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer's disease? An overview of research evidence in the elderly patient population.

Authors:
K Rygiel

J Postgrad Med 2016 Oct-Dec;62(4):242-248

Department of Family Practice, Medical University of Silesia (SUM), Katowice-Zabrze, 3 Maja St. 13/15, 41-800 Zabrze, Poland.

Alzheimer's disease (AD) is a neurodegenerative disease, in which an accumulation of toxic amyloid beta in the brain precedes the emergence of clinical symptoms. AD spectrum consists of presymptomatic, early symptomatic, and symptomatic phase of dementia. At present, no pharmacotherapy exists to modify or reverse a course of AD, and only symptomatic treatments are available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/0022-3859.188553DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5105210PMC
January 2017

Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).

Expert Opin Ther Pat 2016 Nov 13;26(11):1325-1351. Epub 2016 Sep 13.

a Convergence Research Center for Diagnosis, Treatment and Care System of Dementia , Korea Institute of Science and Technology (KIST) , Seongbuk-Gu , Seoul , Republic of Korea.

Introduction: The translocator protein (TSPO) is an emerging target in diverse neurodegenerative diseases. Up-regulated TSPO in the central nervous system (CNS) appears to be involved in neuroinflammatory processes; therefore, the development of potent TSPO ligands is a promising method for alleviating or imaging patients with neurodegenerative diseases. Areas covered: This review will provide an overview of recently developed TSPO ligands patented from 2010 to 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543776.2016.1230606DOI Listing
November 2016

Regulation of Oligodendrocyte Differentiation and Myelination by Nuclear Receptors: Role in Neurodegenerative Disorders.

Adv Exp Med Biol 2016 ;949:287-310

Grupo de Neurociencias y Muerte Celular, Facultad de Medicina e Instituto de Genética, Universidad Nacional de Colombia, Bogotá, Colombia.

During development and through adulthood, differentiation of diverse cell types is controlled by specific genetic and molecular programs for which transcription factors are master regulators of gene expression. Here, we present an overview of the role of nuclear receptors and their selective pharmacological modulators in oligodendrocytes linage, their role in myelination and remyelination and their potential use as a therapeutic strategy for demyelinating diseases. We discuss several aspects of nuclear receptors including: (1) the biochemistry of nuclear receptors superfamily; (2) their role on stem cells physiology, focusing in differentiation and cell removal; (3) the role of nuclear receptor in the oligodendrocytes cell linage, from oligodendrocyte progenitors cells to mature myelinating cells; and (4) the therapeutics opportunities of nuclear receptors for specific demyelinating diseases. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-3-319-40764-7_14
Publisher Site
http://dx.doi.org/10.1007/978-3-319-40764-7_14DOI Listing
September 2017
5 Reads